Article Text

PDF

002.2 Operational performance of a new molecular-based point-of-care test for diagnosis of chlamydia trachomatis and neisseria gonorrhoeae infection: concordance with conventional laboratory testing
  1. LM Causer1,
  2. A Tangey2,
  3. SG Badman1,
  4. B Hengel3,
  5. L Natoli4,
  6. D Speers5,
  7. SN Tabrizi6,
  8. D Whiley7,
  9. DA Anderson4,
  10. J Ward8,
  11. JM Kaldor1,
  12. RJ Guy1 on behalf of the TTANGO investigators
  1. 1Kirby Institute, UNSW, Sydney, NSW, Australia
  2. 2Ngaanyatjarra Health Service, Warburton, WA, Australia
  3. 5Department of Microbiology, PathWest Laboratory Medicine, Nedlands, WA, Australia
  4. 6The Royal Women’s Hospital and Murdoch Childrens Research Institute, Parkville, Vic, Australia
  5. 7Queensland Paediatric Infectious Diseases (QPID) Laboratory, Brisbane, Qld, Australia
  6. 8South Australian Health and Medical Research Institute, Adelaide, SA, Australia
  7. 3Apunipima Cape York Health Council, Cairns, Qld, Australia
  8. 4The Burnet Institute, Melbourne, Vic, Australia

Abstract

Introduction New molecular-based point-of-care (POC) tests for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) infections are being used for the first time by trained Aboriginal health workers/practitioners, registered/enrolled nurses and medical officers in regional/remote health services in Australia as part of TTANGO (Test, Treat ANd GO). We assessed the operational performance of the GeneXpert®CT/NG assay (Cepheid) POC test using conventional laboratory tests as the reference standard.

Methods TTANGO, a randomised cross-over control trial of CT/NG POC testing, commenced June 2013. To date, 12 services have implemented GeneXpert testing on-site as routine practice, with specimens still sent to jurisdictional laboratories for conventional nucleic acid amplification testing (NAAT) as usual. We assessed the concordance of GeneXpert performed by health service staff with conventional laboratory NAAT. We also present selected details of discordant specimens.

Results Among 1995 GeneXpert tests performed, CT and NG were detected in 182 and 127, respectively, by the jurisdictional laboratory. CT concordance was 99.4% (95% CI: 99.0 – 99.8) and NG was 99.9% (99.6–100.0). The fourteen discordant results (eight urines, six lower vaginal swabs) were identified in seven services and five laboratories (two use Cobas 4800, three use Aptima). Discordant results were predominantly CT (n = 12) and most (n = 10) were positive POC/negative laboratory results. The median POC test crossing point among CT discordants was 37.2 (IQR: 31.6–37.7) with five of nine (55.6%) having crossing points >35, compared to 29.2 (IQR: 26.3–32.6) among CT concordants with 10 of 179 (5.5%) having crossing points >35. The two NG discordant results were both positive POC/negative laboratory results.

Conclusion The performance of GeneXpert in the hands of trained health service staff is excellent and consistent with previous laboratory and field evaluations. Higher crossing points of discordant results most likely indicates low organism loads close to test detection threshold and seem unrelated to service, laboratory, specimen type or reference assay. Overall, results show the GeneXpert method is suitable for routine detection of CT and NG.

Disclosure of interest statement No conflicts of interest declared. No financial support was received by Cepheid. Cepheid has provided GeneXpert devices on loan for the duration of TTANGO and test cartridges at a reduced rate.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.